<DOC>
	<DOCNO>NCT00266565</DOCNO>
	<brief_summary>Toxicity anti-IL-5</brief_summary>
	<brief_title>Anti-Interleukin-5 ( IL-5 ) Study Hypereosinophilic Syndrome</brief_title>
	<detailed_description>The purpose study assess toxicity anti-IL-5 , see whether lower peripheral blood eosinophil and/or tissue whether steroid and/or interferon spar effect .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Gastroenteritis</mesh_term>
	<mesh_term>Eosinophilic Esophagitis</mesh_term>
	<mesh_term>Churg-Strauss Syndrome</mesh_term>
	<mesh_term>Hypereosinophilic Syndrome</mesh_term>
	<mesh_term>Enteritis</mesh_term>
	<mesh_term>Eosinophilia</mesh_term>
	<mesh_term>Gastritis</mesh_term>
	<criteria>Adequate renal , cardiac , hepatic function Not pregnant breastfeed A diagnosis hypereosinophilic syndrome : Idiopathic hypereosinophilic syndrome ; Eosinophilia myalgia syndrome ; Eosinophilic gastroenteritis ; ChurgStrauss syndrome ; Eosinophilic cellulitis ; Benign hypereosinophilia ; Eosinophilic esophagitis . Maintained , need , follow : glucocorticoid , interferon , methotrexate , hydroxyurea , cytoxan , 6mercaptopurine , vincristine Blood eosinophil count great 750 cells/mcl Creatinine &gt; 3 X upper limit age AST &gt; 5 X upper limit age Platelet count &lt; 50,000/mm3 Cardiac function : 1 . NYHA class IIIb IV ( patient shortness breath fatigue mild exertion rest ) ; 2 . Patients symptomatic supraventricular ventricular arrythmias require treatment ; 3 . Patients require IV heart failure medication ; 4 . Angina acute myocardial infarction History renal , hepatic , endocrine , oncologic , cardiovascular disease , condition , opinion Investigator , would jeopardize safety patient impact validity study result History allergic adverse response previous antibody type therapy History allergic adverse response antiIL5 therapy Evidence , history , parasitic infection ( within past 1 year ) Participation previous clinical trial involve investigational agent within 30 day prior study initiation Receipt antiIL5 therapy past Blood donation 450 ml ( 1 pint ) within 30 day prior study initiation Abnormal unusual diet substantial change eat habit within 30 day prior , , study . Patients eosinophil level &gt; 750 cells/mcl runin period . Patients eosinophilic infiltration tissue eligible develop eosinophil level &gt; 750 cells/mcl , assume meet eligibility requirement . Positive serum pregnancy test Breastfeeding Unable use effective birth control method duration study Unable unwilling give voluntary inform consent/assent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>